Literature DB >> 12653847

Anti-cytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and/or myasthenia gravis.

A Meager1, M Wadhwa, P Dilger, C Bird, R Thorpe, J Newsom-Davis, N Willcox.   

Abstract

We have screened for spontaneous anticytokine autoantibodies in patients with infections, neoplasms and autoimmune diseases, because of their increasingly reported co-occurrence. We tested for both binding and neutralizing autoantibodies to a range of human cytokines, including interleukin-1alpha (IL-1alpha), IL-1beta, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IL-18, interferon-alpha2 (IFN-alpha2), IFN-omega, IFN-beta, IFN-gamma, tumour necrosis factor alpha (TNF-alpha), transforming growth factor beta-1 (TGF-beta1) and granulocyte-macrophage colony stimulating factor (GM-CSF), in plasmas or sera. With two notable exceptions described below, we found only occasional, mostly low-titre, non-neutralizing antibodies, mainly to GM-CSF; also to IL-10 in pemphigoid. Strikingly, however, high-titre, mainly IgG, autoantibodies to IFN-alpha2, IFN-omega and IL-12 were common at diagnosis in patients with late-onset myasthenia gravis (LOMG+), thymoma (T) but no MG (TMG-) and especially with both thymoma and MG together (TMG+). The antibodies recognized other closely related type I IFN-alpha subtypes, but rarely the distantly related type I IFN-beta, and never (detectably) the unrelated type II IFN-gamma. Antibodies to IL-12 showed a similar distribution to those against IFN-alpha2, although prevalences were slightly lower; correlations between individual titres against each were so modest that they appear to be entirely different specificities. Neither showed any obvious correlations with clinical parameters including thymoma histology and HLA type, but they did increase sharply if the tumours recurred. These antibodies neutralized their respective cytokine in bioassays in vitro; although they persisted for years severe infections were surprisingly uncommon, despite the immunosuppressive therapy also used in most cases. These findings must hold valuable clues to autoimmunizing mechanisms in paraneoplastic autoimmunity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12653847      PMCID: PMC1808678          DOI: 10.1046/j.1365-2249.2003.02113.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  58 in total

1.  Cleavage by granzyme B is strongly predictive of autoantigen status: implications for initiation of autoimmunity.

Authors:  L Casciola-Rosen; F Andrade; D Ulanet; W B Wong; A Rosen
Journal:  J Exp Med       Date:  1999-09-20       Impact factor: 14.307

Review 2.  The control of T cell responses by dendritic cell subsets.

Authors:  S D Reid; G Penna; L Adorini
Journal:  Curr Opin Immunol       Date:  2000-02       Impact factor: 7.486

3.  Neutralizing antibodies to granulocyte-macrophage colony-stimulating factor, interleukin-1alpha and interferon-alpha but not other cytokines in human immunoglobulin preparations.

Authors:  M Wadhwa; A Meager; P Dilger; C Bird; C Dolman; R G Das; R Thorpe
Journal:  Immunology       Date:  2000-01       Impact factor: 7.397

4.  Dendritic cells interact directly with naive B lymphocytes to transfer antigen and initiate class switching in a primary T-dependent response.

Authors:  M Wykes; A Pombo; C Jenkins; G G MacPherson
Journal:  J Immunol       Date:  1998-08-01       Impact factor: 5.422

5.  Spontaneously occurring neutralizing antibodies against granulocyte-macrophage colony-stimulating factor in patients with autoimmune disease.

Authors:  A Meager; M Wadhwa; C Bird; P Dilger; R Thorpe; J Newsom-Davis; N Willcox
Journal:  Immunology       Date:  1999-07       Impact factor: 7.397

Review 6.  How can dendritic cells cause autoimmune disease?

Authors:  H Drakesmith; B Chain; P Beverley
Journal:  Immunol Today       Date:  2000-05

Review 7.  The role of T-cells in the initiation of autoantibody responses in thymoma patients.

Authors:  A Vincent; N Willcox
Journal:  Pathol Res Pract       Date:  1999       Impact factor: 3.250

8.  Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.

Authors:  M B Atkins; M J Robertson; M Gordon; M T Lotze; M DeCoste; J S DuBois; J Ritz; A B Sandler; H D Edington; P D Garzone; J W Mier; C M Canning; L Battiato; H Tahara; M L Sherman
Journal:  Clin Cancer Res       Date:  1997-03       Impact factor: 12.531

9.  Id2 and Id3 inhibit development of CD34(+) stem cells into predendritic cell (pre-DC)2 but not into pre-DC1. Evidence for a lymphoid origin of pre-DC2.

Authors:  H Spits; F Couwenberg; A Q Bakker; K Weijer; C H Uittenbogaart
Journal:  J Exp Med       Date:  2000-12-18       Impact factor: 14.307

10.  Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor.

Authors:  T Kitamura; N Tanaka; J Watanabe; S Kanegasaki; Y Yamada; K Nakata
Journal:  J Exp Med       Date:  1999-09-20       Impact factor: 14.307

View more
  56 in total

Review 1.  Accessing the human repertoire for broadly neutralizing HIV antibodies.

Authors:  Philip W Hammond
Journal:  MAbs       Date:  2010 Mar-Apr       Impact factor: 5.857

Review 2.  Current methods for detecting antibodies against erythropoietin and other recombinant proteins.

Authors:  Robin Thorpe; Steven J Swanson
Journal:  Clin Diagn Lab Immunol       Date:  2005-01

3.  Anti-cytokine autoantibodies in autoimmune diseases.

Authors:  Giuseppe Cappellano; Elisabetta Orilieri; Abiy D Woldetsadik; Elena Boggio; Maria F Soluri; Cristoforo Comi; Daniele Sblattero; Annalisa Chiocchetti; Umberto Dianzani
Journal:  Am J Clin Exp Immunol       Date:  2012-11-15

4.  Recurrent Burkholderia gladioli suppurative lymphadenitis associated with neutralizing anti-IL-12p70 autoantibodies.

Authors:  Bich-Thuy T Sim; Sarah K Browne; Marguerite Vigliani; Dalila Zachary; Lindsey Rosen; Steven M Holland; Steven M Opal
Journal:  J Clin Immunol       Date:  2013-05-26       Impact factor: 8.317

Review 5.  Searching for biomarkers: humoral response profiling with luciferase immunoprecipitation systems.

Authors:  Peter D Burbelo; Kathryn H Ching; Kathleen E Bren; Michael J Iadarola
Journal:  Expert Rev Proteomics       Date:  2011-06       Impact factor: 3.940

6.  IL-2 antibodies in type 1 diabetes and during IL-2 therapy.

Authors:  Guillaume Churlaud; Michelle Rosenzwajg; Patrice Cacoub; David Saadoun; Dominique Valteau-Couanet; Nathalie Chaput; Alberto Pugliese; David Klatzmann
Journal:  Diabetologia       Date:  2018-06-02       Impact factor: 10.122

Review 7.  Thymic tolerance as a key brake on autoimmunity.

Authors:  Mickie Cheng; Mark S Anderson
Journal:  Nat Immunol       Date:  2018-06-20       Impact factor: 25.606

8.  Patients with inflammatory bowel disease may have a transforming growth factor-beta-, interleukin (IL)-2- or IL-10-deficient state induced by intrinsic neutralizing antibodies.

Authors:  E C Ebert; A Panja; K M Das; R Praveen; X Geng; C Rezac; M Bajpai
Journal:  Clin Exp Immunol       Date:  2009-01       Impact factor: 4.330

9.  A robust immunoassay for anti-interferon autoantibodies that is highly specific for patients with autoimmune polyglandular syndrome type 1.

Authors:  Li Zhang; Jennifer M Barker; Sunanda Babu; Maureen Su; Matthew Stenerson; Mickie Cheng; Anthony Shum; Ehud Zamir; Raffaele Badolato; Adam Law; George S Eisenbarth; Mark S Anderson
Journal:  Clin Immunol       Date:  2007-09-06       Impact factor: 3.969

10.  Autoimmunity as a predisposition for infectious diseases.

Authors:  Mohan S Maddur; Janakiraman Vani; Sébastien Lacroix-Desmazes; Srinivas Kaveri; Jagadeesh Bayry
Journal:  PLoS Pathog       Date:  2010-11-04       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.